Quest Diagnostics Guides FY26 EPS to $9.45–$9.65, Raises Dividend 7.5%
Quest Diagnostics guided FY26 earnings to $9.45–$9.65 per share and adjusted EPS to $10.50–$10.70 on $11.70–$11.82 billion revenue, topping analysts’ $10.42 EPS and $11.38 billion sales forecasts. The board raised its quarterly dividend 7.5% to $0.86 and added $1 billion to buyback authority.
1. FY26 Guidance
Quest Diagnostics initiated guidance for fiscal 2026, projecting GAAP earnings of $9.45 to $9.65 per share and adjusted EPS of $10.50 to $10.70 on revenues of $11.70 billion to $11.82 billion, exceeding consensus estimates of $10.42 per share and $11.38 billion in sales.
2. Dividend Increase
The board approved a 7.5% increase in the quarterly cash dividend, raising it from $0.80 to $0.86 per share, payable April 20, 2026, to shareholders of record on April 6, 2026.
3. Share Repurchase Authorization
Directors authorized an additional $1 billion in share repurchases, augmenting the $0.4 billion remaining under the program as of December 31, 2025, to support continued capital returns.